Loading...
Loading...
Alkermes
plc
ALKS today presented positive results from a phase 1
study of ALKS 3831, a novel drug candidate for the treatment of
schizophrenia, in an oral session at the 53rd Annual New
Clinical Drug Evaluation Unit (NCDEU) Meeting in Hollywood, Fla. By
combining a novel opioid modulator, ALKS 33, and olanzapine, an
antipsychotic drug commercially available as ZYPREXA®, ALKS
3831 is designed to be a broad spectrum treatment for schizophrenia with
the potential benefits of reduced weight gain associated with olanzapine
and expanded utility in patients with schizophrenia and comorbid
substance abuse.
In the phase 1 study, subjects who received once-daily, oral
administration of ALKS
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in